Company Description
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE.
The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105.
Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
| Country | Netherlands |
| Founded | 1988 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 382 |
| CEO | Dr. Sijmen de Vries M.B.A., M.D. |
Contact Details
Address: Darwinweg 24 Leiden, P7 2333 CR Netherlands | |
| Phone | 31 (0)71 5247 400 |
| Website | pharming.com |
Stock Details
| Ticker Symbol | PHAR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 0001828316 |
| CUSIP Number | 71716E105 |
| ISIN Number | US71716E1055 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sijmen de Vries M.B.A., M.D. | President, Chief Executive Officer and Executive Director |
| Jeroen Wakkerman | Chief Financial Officer |
| Mireille Sanders M.Sc. | Chief Operations Officer |
| Susanne Embleton | Investor Relations Manager |
| Ruud Van Outersterp | Chief Ethics and Compliance Officer |
| Dr. Anurag Relan M.D., MPH | Chief Medical Officer |
| Stephen Toor | Chief Commercial Officer and GM Americas |
| Dr. Alexander Breidenbach M.B.A. | Chief Business Officer |
| Dr. Bruno M. L. Giannetti | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 30, 2024 | 6-K | Report of foreign issuer |
| May 21, 2024 | 6-K | Report of foreign issuer |
| May 15, 2024 | 6-K | Report of foreign issuer |
| May 8, 2024 | 6-K | Report of foreign issuer |
| Apr 25, 2024 | 6-K | Report of foreign issuer |
| Apr 24, 2024 | 6-K | Report of foreign issuer |
| Apr 8, 2024 | 6-K | Report of foreign issuer |
| Apr 4, 2024 | 6-K | Report of foreign issuer |
| Apr 4, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 14, 2024 | 6-K | Report of foreign issuer |